Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
DA Reardon, JA Quinn, JJ Vredenburgh… - Clinical Cancer …, 2006 - AACR
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
[PDF][PDF] Phase 1Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
DA Reardon, JA Quinn, JJ Vredenburgh… - Clin Cancer …, 2006 - academia.edu
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
DA Reardon, JA Quinn… - … : an official journal …, 2006 - pubmed.ncbi.nlm.nih.gov
Purpose To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
[PDF][PDF] Phase 1Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
DA Reardon, JA Quinn, JJ Vredenburgh… - Clin Cancer …, 2006 - researchgate.net
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
DA Reardon, JA Quinn, JJ Vredenburgh… - … Cancer Research: an …, 2006 - europepmc.org
Purpose To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of
gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
DA Reardon, JA Quinn… - Clinical Cancer …, 2006 - mahidol.elsevierpure.com
Purpose: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
of gefitinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus …
[引用][C] Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma
DA Reardon, JA Quinn, JJ Vredenburgh… - Clinical Cancer …, 2006 - cir.nii.ac.jp
Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[引用][C] Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
DA REARDON, JA QUINN… - Clinical cancer …, 2006 - pascal-francis.inist.fr
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …